2023
DOI: 10.1002/adfm.202370008
|View full text |Cite
|
Sign up to set email alerts
|

A Chlorotoxin‐Directed Diselenide‐Bridged Tumor‐Homing Persistent Luminescence Nanoprobes Mediating Inhibition of Oxidative Phosphorylation for Long‐Term Near‐Infrared Imaging and Therapy of Glioblastoma (Adv. Funct. Mater. 1/2023)

Abstract: Glioblastoma Targeted Therapy In article number 2209579, Wang and co‐workers report a near‐infrared persistent luminescence nanoparticle for the diagnosis and targeted therapy of glioblastoma (GBM). GBM cell membrane (GCM) coating and chlorotoxin enhanced the blood‐brain barrier (BBB) penetration and the targeting and tumor‐homing of GBM. This study offers an example of the highly promising drug carriers for precise diagnosis and therapy of central nervous system diseases.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
5
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 0 publications
0
5
0
Order By: Relevance
“…Table 2 depicts some strategies using diselenide‐based compounds combined with nanoformulations to potentiate anticancer effects, directing drug delivery, and the main outcomes. Diorganyl diselenides have potentiated their anticancer effects when incorporated into nanocapsules (inside or coating them) as anti‐glioma treatment, being suitable for intravenous administration, [326] as nanoprobes, [327] cross‐linked with carboxymethyl chitosan [328] and also, contributing to the suppression of tumor growth [329–331] . Yang and coworkers illustrated that employing diselenide‐bridged mesoporous silica nanoparticles (MSNs) for light‐responsive degradation and dual drug release results in synergistic anti‐tumor and minimal adverse off‐target effects [332] .…”
Section: Pharmacology Of Diorganyl Diselenidesmentioning
confidence: 99%
“…Table 2 depicts some strategies using diselenide‐based compounds combined with nanoformulations to potentiate anticancer effects, directing drug delivery, and the main outcomes. Diorganyl diselenides have potentiated their anticancer effects when incorporated into nanocapsules (inside or coating them) as anti‐glioma treatment, being suitable for intravenous administration, [326] as nanoprobes, [327] cross‐linked with carboxymethyl chitosan [328] and also, contributing to the suppression of tumor growth [329–331] . Yang and coworkers illustrated that employing diselenide‐bridged mesoporous silica nanoparticles (MSNs) for light‐responsive degradation and dual drug release results in synergistic anti‐tumor and minimal adverse off‐target effects [332] .…”
Section: Pharmacology Of Diorganyl Diselenidesmentioning
confidence: 99%
“…ZnGa 2 O 4 as classical host has been reported for persistent NIR fluorescence imaging. [ 78 ] For instance, Kong et al. prepared ZnGa 2 O 4 :Cr 3+ , Sn 4+ (ZGO) with 695 nm persistent luminescence under UV light irradiation.…”
Section: Nir Light Responsive Materials For Imaging Diagnosis Of Brai...mentioning
confidence: 99%
“…[ 136,137 ] For example, the fluorescence of some persistent luminescence nanoprobes can last for several minutes to hours, making them valuable for monitoring the tumor size and long‐term imaging with significantly improved sensitivity. [ 138–140 ] Several diagnostic and therapeutic NPs have been developed based on the strong luminescence of metal nanoclusters (MNCs) in combination with multiple treatment methods, which have promising development prospects in cancer therapeutic evaluation. [ 141,142 ] In addition to strong luminescence, MNCs have the ability to produce ROS and photothermal effects under excited light, thereby showing PDT capacity.…”
Section: Luminescence Nanoprobe‐mediated Therapeutic Evaluationsmentioning
confidence: 99%